AnaMar strengthens financial position

Press release
August 22, 2008


AnaMar strengthens financial position

LinkMed's portfolio company AnaMar Medical is strengthening its financial
position through a directed share issue worth SEK 20 million. The two principal
owners LinkMed and Koncentra Holding are each investing SEK 10 million in the
issue.

AnaMar Medical is strengthening its financial position through a directed share
issue prior to carrying out a first round of clinical trials on humans (Phase 1)
with MCR (AM240) to combat chronic joint disease. The trials are planned for the
second half of 2008. AnaMar Medical's principal shareholders Koncentra Holding
and LinkMed are participating in the issue on equal terms with an investment of
SEK 10 million each. 

LinkMed's ownership stake in AnaMar Medical is 24.9% percent.

About AnaMar Medical
AnaMar Medical develops drugs and biomarkers for diagnosing and
monitoring/predicting chronic joint diseases such as rheumatoid arthritis and
chronic joint inflammation. AnaMar Medical has five drug candidates in
preclinical trials, two biomarkers in prototype development and two commercially
available biomarkers, COMP®-Elisa and Animal COMP-Elisa.


For more information contact:
LinkMed CEO, Ingemar Lagerlöf, tel. +46 8 508 939 93


LinkMed, in collaboration with innovators, develops life science companies. By
contributing entrepreneurship and capital, LinkMed has created a portfolio of
twelve companies, seven in biotechnology and five in medical technology. The
company's principal owners are FastPartner, Koncentra Holding, and the founder
Ingemar Lagerlöf. The LinkMed share is listed on the OMX Nordic Exchange
Stockholm in the small-cap sector (ticker:LMED).